IL255185A0 - 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto - Google Patents
1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related theretoInfo
- Publication number
- IL255185A0 IL255185A0 IL255185A IL25518517A IL255185A0 IL 255185 A0 IL255185 A0 IL 255185A0 IL 255185 A IL255185 A IL 255185A IL 25518517 A IL25518517 A IL 25518517A IL 255185 A0 IL255185 A0 IL 255185A0
- Authority
- IL
- Israel
- Prior art keywords
- gpr52
- carboxamides
- indoline
- modulators
- heteroaryl
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154523P | 2015-04-29 | 2015-04-29 | |
| PCT/US2016/030105 WO2016176571A1 (en) | 2015-04-29 | 2016-04-29 | 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL255185A0 true IL255185A0 (en) | 2017-12-31 |
Family
ID=56015108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL255185A IL255185A0 (en) | 2015-04-29 | 2017-10-22 | 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9676758B2 (https=) |
| EP (1) | EP3292114B1 (https=) |
| JP (1) | JP6673939B2 (https=) |
| KR (1) | KR20180004193A (https=) |
| CN (1) | CN108174603B (https=) |
| AU (1) | AU2016255510A1 (https=) |
| BR (1) | BR112017022987A2 (https=) |
| CA (1) | CA2984153A1 (https=) |
| CL (1) | CL2017002738A1 (https=) |
| EA (1) | EA034244B1 (https=) |
| ES (1) | ES2784316T3 (https=) |
| IL (1) | IL255185A0 (https=) |
| MX (1) | MX373876B (https=) |
| PH (1) | PH12017501961A1 (https=) |
| WO (1) | WO2016176571A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111792990A (zh) * | 2019-04-09 | 2020-10-20 | 中国科学院上海药物研究所 | 一种不饱和酮类化合物、其制备方法和用途 |
| AU2020381168A1 (en) * | 2019-11-08 | 2022-04-14 | Nxera Pharma Uk Limited | GPR52 modulator compounds |
| GB202003668D0 (en) | 2020-03-13 | 2020-04-29 | Heptares Therapeutics Ltd | GPR52 Modulator compounds |
| BR112022018996A2 (pt) * | 2020-03-30 | 2022-11-01 | Boehringer Ingelheim Int | 3-fenoxiazetidin-1-il-pirazinas substituídas apresentando atividade agonística do gpr52". |
| WO2021216705A1 (en) * | 2020-04-22 | 2021-10-28 | Neurocrine Biosciences, Inc. | Gpr52 modulators and methods of use |
| GB202013558D0 (en) | 2020-08-28 | 2020-10-14 | Heptares Therapeutics Ltd | GRP52 Modularor compounds |
| WO2022232017A1 (en) | 2021-04-26 | 2022-11-03 | Neurocrine Biosciences, Inc. | Gpr52 modulators and methods of use |
| JP2024533565A (ja) | 2021-09-14 | 2024-09-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ３－フェノキシアゼチジン－１－イル－ヘテロアリールピロリジン誘導体及び医薬としてのその使用 |
| GB202113186D0 (en) | 2021-09-15 | 2021-10-27 | Heptares Therapeutics Ltd | GPR52 Modulator compounds |
| WO2024091542A1 (en) * | 2022-10-26 | 2024-05-02 | Neurocrine Biosciences, Inc. | Compounds and compositions as gpr52 modulators |
| WO2024091541A1 (en) * | 2022-10-26 | 2024-05-02 | Neurocrine Biosciences, Inc. | Compounds and compositions as gpr52 modulators |
| AR130864A1 (es) * | 2022-10-26 | 2025-01-29 | Neurocrine Biosciences Inc | Compuestos y composiciones como moduladores de gpr52 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2043744A2 (en) * | 2006-07-13 | 2009-04-08 | SmithKline Beecham Corporation | Chemical compounds |
| US20110009421A1 (en) * | 2008-02-27 | 2011-01-13 | Takeda Pharmaceutical Company Limited | Compound having 6-membered aromatic ring |
| FR2928645A1 (fr) * | 2008-03-14 | 2009-09-18 | Sanofi Aventis Sa | Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation |
| JPWO2009157196A1 (ja) * | 2008-06-25 | 2011-12-08 | 武田薬品工業株式会社 | アミド化合物 |
| TW201010977A (en) | 2008-08-12 | 2010-03-16 | Takeda Pharmaceutical | Amide compound |
| US8481731B2 (en) * | 2009-06-24 | 2013-07-09 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical composition and methods relating thereto |
| JP2012082175A (ja) * | 2010-10-14 | 2012-04-26 | Daiichi Sankyo Co Ltd | インドリン化合物を含有する医薬組成物 |
-
2016
- 2016-04-29 CN CN201680038190.3A patent/CN108174603B/zh active Active
- 2016-04-29 MX MX2017013853A patent/MX373876B/es active IP Right Grant
- 2016-04-29 EA EA201792375A patent/EA034244B1/ru not_active IP Right Cessation
- 2016-04-29 KR KR1020177034516A patent/KR20180004193A/ko not_active Withdrawn
- 2016-04-29 AU AU2016255510A patent/AU2016255510A1/en not_active Abandoned
- 2016-04-29 US US15/143,026 patent/US9676758B2/en active Active
- 2016-04-29 BR BR112017022987A patent/BR112017022987A2/pt not_active Application Discontinuation
- 2016-04-29 CA CA2984153A patent/CA2984153A1/en not_active Abandoned
- 2016-04-29 EP EP16723592.8A patent/EP3292114B1/en active Active
- 2016-04-29 ES ES16723592T patent/ES2784316T3/es active Active
- 2016-04-29 JP JP2017556818A patent/JP6673939B2/ja active Active
- 2016-04-29 WO PCT/US2016/030105 patent/WO2016176571A1/en not_active Ceased
-
2017
- 2017-10-22 IL IL255185A patent/IL255185A0/en unknown
- 2017-10-27 PH PH12017501961A patent/PH12017501961A1/en unknown
- 2017-10-30 CL CL2017002738A patent/CL2017002738A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA034244B1 (ru) | 2020-01-21 |
| US20160318911A1 (en) | 2016-11-03 |
| EP3292114A1 (en) | 2018-03-14 |
| CA2984153A1 (en) | 2016-11-03 |
| EP3292114B1 (en) | 2020-03-11 |
| AU2016255510A1 (en) | 2017-11-23 |
| US9676758B2 (en) | 2017-06-13 |
| JP6673939B2 (ja) | 2020-04-01 |
| MX2017013853A (es) | 2018-06-07 |
| WO2016176571A1 (en) | 2016-11-03 |
| CL2017002738A1 (es) | 2018-06-01 |
| KR20180004193A (ko) | 2018-01-10 |
| ES2784316T3 (es) | 2020-09-24 |
| JP2018519253A (ja) | 2018-07-19 |
| BR112017022987A2 (pt) | 2018-07-24 |
| CN108174603A (zh) | 2018-06-15 |
| EA201792375A1 (ru) | 2018-05-31 |
| CN108174603B (zh) | 2021-07-02 |
| PH12017501961A1 (en) | 2018-03-26 |
| MX373876B (es) | 2020-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285151A (en) | Methods of treating fgf21-associated disorders | |
| IL247452A0 (en) | Compounds for treatment of complement mediated disorders | |
| IL255185A0 (en) | 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto | |
| HUE064141T2 (hu) | Azolopirimidin rákkal összefüggõ rendellenességek kezelésére | |
| DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| IL256166B (en) | Compounds for use in treating neuromuscular disorders | |
| LT3334422T (lt) | Kanabidiolio rūgšties panaudojimas epilepsijos gydymui | |
| IL253945B (en) | kdm1a inhibitors to treat the disease | |
| DK3331876T3 (da) | Modulators of ror-gamma | |
| DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| HUE055263T2 (hu) | 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére | |
| IL262852A (en) | Treatment of complement-mediated disorders | |
| HUE056287T2 (hu) | Pancreatitis kezelése | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
| DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
| SG11201608729RA (en) | Membrane-adherent self-assembled systems for treatment of ocular disorders | |
| DK3192524T3 (da) | Hgf præparat egnet til behandling af neurologiske lidelser | |
| LT3307267T (lt) | Išsėtinės sklerozės gydymas | |
| DK3220952T3 (da) | Fremgangsmåde til behandling eller forebyggelse af slagtilfælde | |
| HUE064604T2 (hu) | Menotropin meddõség kezelésére | |
| DK3439661T3 (da) | Fremgangsmåder til behandling af øjenlidelser |